BioAge Labs (NASDAQ:BIOA) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of BioAge Labs (NASDAQ:BIOA) from a hold rating to a sell rating in a research report sent to investors on Saturday.

A number of other research firms have also commented on BIOA. Citigroup upped their price target on shares of BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Thursday, October 30th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, BioAge Labs currently has a consensus rating of “Hold” and an average price target of $15.00.

BioAge Labs Trading Up 0.8%

Shares of BIOA opened at $14.03 on Friday. BioAge Labs has a 12-month low of $2.88 and a 12-month high of $16.43. The company has a market cap of $502.98 million, a P/E ratio of -9.23 and a beta of 1.38. The firm’s 50-day simple moving average is $10.90.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.11. The firm had revenue of $2.05 million for the quarter.

Insider Transactions at BioAge Labs

In other BioAge Labs news, insider Paul D. Rubin sold 68,897 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $10.19, for a total transaction of $702,060.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 20.82% of the company’s stock.

Institutional Investors Weigh In On BioAge Labs

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Public Employees Retirement System of Ohio bought a new position in shares of BioAge Labs in the second quarter worth about $57,000. Geode Capital Management LLC increased its position in BioAge Labs by 60.8% in the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock worth $1,873,000 after purchasing an additional 171,426 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of BioAge Labs during the 2nd quarter valued at about $27,000. Intech Investment Management LLC bought a new stake in shares of BioAge Labs in the 2nd quarter valued at approximately $60,000. Finally, Jefferies Financial Group Inc. purchased a new position in BioAge Labs during the second quarter worth $206,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.